Talecris Biotherapeutics, a former Bayer maker of plasma-derived protein therapies LBO'd by Cerberus, raised $950 million on Wednesday by offering 50 million shares at $19.00, at the midpoint of the $18.00 to $20.00 range. The deal was 12% larger than expected, with selling shareholders Cerberus Capital and Ampersand Ventures offering an additional 5.3 million shares. Talecris Biotherapeutics is expected to begin trading Thursday on the NASDAQ under the symbol TLCR. Morgan Stanley, Goldman Sachs, and Citi acted as lead managers on the deal.
